Optimization of a Decision Formula for Optimal Timing of Immunosuppressive Therapy Initiation in Primary Membranous Nephropathy: A Multicenter Retrospective Cohort Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

282 participants

Study Classification

OBSERVATIONAL

Study Start Date

1990-01-01

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to optimize the evaluation formula for the timing of initiating immunosuppressive therapy in primary membranous nephropathy in patients with primary membranous nephropathy. The main question it aims to answer is:When should immunosuppressive therapy be initiated?This study is a retrospective one. Participants will not receive any treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Different Immunosuppressive Treatment in iMN

NCT04745728

Idiopathic Membranous Nephropathy

RECRUITING PHASE3

The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I.

NCT03466801

Idiopathic Membranous Nephropathy

TERMINATED NA

An Outcome Analysis of Primary Membranous Nephropathy

NCT06242327

Membranous Nephropathy

ACTIVE_NOT_RECRUITING

Treatment of Patients With Idiopathic Membranous Nephropathy

NCT00135954

Glomerulonephritis, Membranous

COMPLETED PHASE3

Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy

NCT05514015

Primary Membranous Nephropathy

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Membranous Nephropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Modeling Group

The data of this group of participants are used to construct the evaluation formula.

No interventions assigned to this group

Verification group

The data of this group of participants are used to verify the evaluation formula constructed through the modeling group.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* It meets one of the diagnostic criteria for PMN as stipulated in the KDIGO 2021 Clinical Practice Guidelines for the Management of Glomerular Diseases: patients with a clear diagnosis of PMN based on renal biopsy pathology or presenting with nephrotic syndrome and positive anti-PLA2R antibody detection (\>14RU/mL), and excluding secondary factors such as tumors, infections, drugs, and systemic autoimmune diseases.

Exclusion Criteria

* (1) Patients who have received treatment with immunosuppressive medications other than oral prednisolone.

(2) The time interval between the renal biopsy and the baseline measurement is longer than 3 years.

(3) Initiate the use of immunosuppressive agents within 1 week after the diagnosis of PMN.

(4) Participate in the immunosuppressive treatment trial during the follow-up period and be in the intervention group.

Eligible Sex

ALL

Accepts Healthy Volunteers

No